Start here if you're new
what it is
It is an 18-person biotech trying to turn peptide drugs into pills.
how it gets paid
Last year Entera Bio made $181K in revenue. Collaboration revenue was the main engine at $104K, or 58% of sales.
what just happened
The quarter brought in $42K of revenue, and gross margin sat at 0.0%.
At a glance
C++ balance sheet — some cracks in the foundation
40/100 earnings predictability — expect surprises
-$0.25 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
xvary composite: 41/100 — below average
What they do
It is an 18-person biotech trying to turn peptide drugs into pills.
EB613 is the first oral once-daily PTH tablet in the pipeline. Oral tablet → pill form → so you are not tied to injections. Entera has 18 employees, so one program has to carry the weight of the whole shop.
How they make money
$181K
annual revenue
Collaboration revenue
$104K
Research grants
$49K
License fees
$18K
Other income
$10K
The products that matter
oral PTH for osteoporosis
EB613
Phase 3-ready
It is the lead asset, and the company submitted its Phase 3 protocol to regulators in March 2026. For a business with $181K in annual revenue, this is the number-one value driver.
lead asset
oral biologics delivery platform
Oral Delivery Platform
$181K annual revenue
This platform generated the company’s total annual revenue of $181K through collaborations. In plain English: the science may be interesting, but the business model has not been proven commercially.
platform
capital base for trials
2025 financing runway
$35M raised
The $35M capital raise in 2025 matters because it funds the next chapter. It does not change the fact that today’s valuation still rests on clinical execution, not operating cash flow.
funding
Key numbers
-$0.25
fy2024 eps est
$0M
fy2024 rev est
5.3x
trailing p/e
You're paying about 5.3x the last full year's earnings.
0.0%
gross margin
Gross profit kept about 0.0% of each revenue dollar.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ENTX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The quarter brought in $42K of revenue, and gross margin sat at 0.0%.
EDGAR showed a tiny quarter for a tiny company. Revenue still came from a business with 18 employees, not product sales.
$42K
revenue
$0.18
eps
0.0%
gross margin
gross margin
Gross margin was 0.0%, which means every revenue dollar had nowhere to go but out.
source: EDGAR quarterly filing
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Phase 3 failure or delay for EB613.
med
EB613 does not clear the next clinical gate
The lead asset is Phase 3-ready, and the company submitted its protocol in March 2026. If regulators push back or the trial disappoints, nearly all of the current equity story breaks at once.
A $58M market cap supported by a pre-commercial pipeline can compress fast when the lead program stumbles.
med
Cash burn leads to more dilution
The business produced just $181K in annual revenue, so trials are funded by capital markets, not operations. The $35M raise in 2025 helps, but it does not make financing risk disappear.
More equity issuance would spread the same asset base across more shares. Existing holders feel that immediately.
med
The platform story stays theoretical
Management is selling the promise of oral biologics, but the page shows only $181K of collaboration revenue and no commercial product sales. If that number does not start to grow, the platform remains an idea with a ticker.
That would pressure both partnering credibility and the premium valuation investors assign to the technology.
Almost all of the current case rests on assets that are not commercial yet. With $181K in revenue against a $58M valuation, execution risk is the whole story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
FDA feedback on the March 2026 Phase 3 protocol submission
This is the next real checkpoint for EB613. A clean path to trial matters more than another quarter of tiny revenue.
cash
whether the $35M raise is stretching far enough
You want to see the company fund development without rushing back to the market too quickly. Pre-commercial biotech math gets ugly when financing windows close.
validation
signs the platform is becoming more than one asset
With only $181K in annual revenue, any meaningful expansion in collaboration activity would matter. Right now the platform claim still needs proof.
timeline
the next earnings update on March 27, 2026
Do not overfocus on the EPS line. Watch for trial timing, operating expense discipline, and anything that changes the runway picture.
Analyst rankings
earnings predictability
40 / 100
This is a low predictability score. In human-speak, analysts do not trust quarterly numbers to tell the story cleanly.
risk rank
3
Rank 3 means roughly middle-of-the-pack on this dataset. For a clinical-stage biotech, “middle” is still not calm.
beta
1.25
Beta measures how much the stock moves relative to the market. At 1.25, ENTX has historically moved more than the index.
source: institutional data
Institutional activity
institutional ownership data for ENTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive